The tissue renin-angiotensin system and its role in the pathogenesis of major human diseases: quo vadis?

B Saravi, Z Li, CN Lang, B Schmid, FK Lang, S Grad… - Cells, 2021 - mdpi.com
Evidence has arisen in recent years suggesting that a tissue renin-angiotensin system
(tRAS) is involved in the progression of various human diseases. This system contains two …

The potential therapeutic use of renin–angiotensin system inhibitors in the treatment of inflammatory diseases

R Ranjbar, M Shafiee, AR Hesari… - Journal of cellular …, 2019 - Wiley Online Library
Inflammation is a normal part of the immune response to injury or infection but its
dysregulation promotes the development of inflammatory diseases, which cause …

Oxidative stress and early atherosclerosis: novel antioxidant treatment

D Tousoulis, T Psaltopoulou, E Androulakis… - … Drugs and Therapy, 2015 - Springer
Atherosclerotic lesions initiate in regions characterized by low shear stress and reduced
activity of endothelial atheroprotective molecules such as nitric oxide, which is the key …

Angiotensin receptor blockers: Focus on cardiac and renal injury

S Arumugam, R Sreedhar, RA Thandavarayan… - Trends in cardiovascular …, 2016 - Elsevier
Angiotensin II, an important component of renin angiotensin system, is a potent vasopressor
and its actions are mostly mediated via angiotensin II type 1 receptor (AT 1 R) and role of AT …

Possible role of LCZ696 in atherosclerosis: new inroads and perspective

HM Al-Kuraishy, AI Al-Gareeb, E Elekhnawy… - Molecular and Cellular …, 2024 - Springer
LCZ696 blocks both angiotensin receptor type 1 (ATR1) and neprilysin (NEP), which are
intricate in the degradation of natriuretic peptides (NPs) and other endogenous peptides. It …

Angiotensin type 1 receptor blockers in heart failure

KD Singh, SS Karnik - Current drug targets, 2020 - ingentaconnect.com
Homeostasis in the cardiovascular system is maintained by physiological functions of the
Renin Angiotensin Aldosterone System (RAAS). In pathophysiological conditions, over …

The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis

Y Li, S Deng, B Liu, Y Yan, J Du, Y Li, X Jing, Y Liu… - Scientific reports, 2021 - nature.com
To assess the influence of lipid-lowering therapy on coronary plaque volume, and to identify
the LDL and HDL targets for plaque regression to provide a comprehensive overview. The …

Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound

WQ Gao, QZ Feng, YF Li, YX Li, Y Huang… - BMC Cardiovascular …, 2014 - Springer
Background Conflicting results currently exist on the effects of LDL-C levels and statins
therapy on coronary atherosclerotic plaque, and the target level of LDL-C resulting in the …

Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic

M Volpe, G Tocci - Vascular Health and Risk Management, 2012 - Taylor & Francis
Hypertension is a growing global health problem, and is predicted to affect 1.56 billion
people by 2025. Treatment remains suboptimal, with control of blood pressure achieved in …

Effect of angiotensin II type I receptor blockade with valsartan on carotid artery atherosclerosis: a double blind randomized clinical trial comparing valsartan and …

R Ramadan, SS Dhawan, JNG Binongo… - American heart …, 2016 - Elsevier
Background Progression of atherosclerosis is associated with a greater risk for adverse
outcomes. Angiotensin II plays a key role in the pathogenesis and progression of …